Prostate Cancer - Results from #660

Trends in Active Surveillance for Men With Intermediate-Risk Prostate Cancer. August 23, 2024

Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled Trial. August 23, 2024

Patient Preferences for Attributes of Androgen Deprivation Therapies in Prostate Cancer: A Discrete Choice Experiment with Latent Class Analysis. August 23, 2024

How Can Participant Experience of Quality-of-Life Research Be Improved in Cancer Research: Views of the Patient and Public Involvement Representatives from the STAMPEDE2 Prostate Cancer Trial. August 23, 2024

Clinical Factors That Influence Repeat 68Ga-PSMA-11 PET/CT Scan Positivity in Patients with Recurrent Prostate Cancer Under Observation After a Negative 68Ga-PSMA-11 PET/CT Scan: A Single-Center Retrospective Study. August 23, 2024

HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES. August 23, 2024

Current therapy and drug resistance in metastatic castration-resistant prostate cancer. August 23, 2024

Clarity receives FDA Fast Track Designation for 64Cu-SAR- bisPSMA August 22, 2024

Suicide Attempt and Suicide Death Among Spouses of Patients With Cancer August 22, 2024

Precision Drug Olaparib May Be Effective Without Hormone Therapy for Some Men with Biochemically Recurrent Prostate Cancer August 22, 2024

Radiotherapy and immunology August 22, 2024

Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial. August 22, 2024

Assessing sociodemographic and regional disparities in Oncotype DX Genomic Prostate Score uptake. August 22, 2024

PSMA-Targeted 2-Deoxyglucose-Based Dendrimer Nanomedicine for the Treatment of Prostate Cancer. August 22, 2024

Epigenome-wide association study of prostate cancer in African American men identified differentially methylated genes. August 22, 2024

Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studies. August 22, 2024

Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort. August 21, 2024

Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu-PSMA-617 (VISION Trial). August 21, 2024

Prostate-Specific Antigen Screening and Prostate Cancer Mortality: An Emulation of Target Trials in US Medicare. August 21, 2024

Moderately hypofractionated dose escalation radiotherapy for localized prostate cancer, ESHYPRO: Results of a retrospective single-centre series evaluating safety and efficacy. August 21, 2024

Page 34 of 1450